Xcout Intel
NurExone Biologic Inc.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Subscribe to see NurExone Biologic Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NurExone Biologic Inc. at a glance
NurExone Biologic Inc. is a biotech company headquartered in Toronto, Canada. It is publicly listed (NRX) with a market capitalisation of $23.3M. Xcout tracks 11 named people at NurExone Biologic Inc., including Eran Ovadya (Chief Financial Officer).
NurExone Biologic Inc. leadership
- Eran OvadyaChief Financial Officer
- Yoram DruckerChairman of the Board
- Eran OvadyaExecutive Officer
- Lior ShaltielExecutive Officer
- Yoram DruckerExecutive Officer
- Eyal GabbaiDirector
5 more named people on record for NurExone Biologic Inc., with roles, board committees and tenure — see the full roster →
NurExone Biologic Inc. competitors
A few of NurExone Biologic Inc.'s closest competitors — see the full list of competitors and alternatives →
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Aptose Biosciences Inc. is a clinical-stage biotechnology company that develops small molecule cancer therapeutics, focusing on precision medicines for hematologic malignancies. The company's product pipeline features investigational drug candidates such as tuspetinib and luxeptinib, which are designed to treat conditions like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies.
NanoVation Therapeutics is a platform developer headquartered in Vancouver, British Columbia, that partners with leading pharmaceutical and biotech companies to enable genetic medicines.
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Get NurExone Biologic Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on NurExone Biologic Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access